Pizzoferrato M, Puca P, Ennas S, Cammarota G, Guidi L. Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure. World J Gastroenterol 2022; 28(44): 6258-6270 [PMID: 36504557 DOI: 10.3748/wjg.v28.i44.6258]
Corresponding Author of This Article
Luisa Guidi, MD, PhD, Professor, UOC Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, Rome 00168, Italy. luisa.guidi@policlinicogemelli.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 28, 2022; 28(44): 6258-6270 Published online Nov 28, 2022. doi: 10.3748/wjg.v28.i44.6258
Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
Marco Pizzoferrato, Pierluigi Puca, Sara Ennas, Giovanni Cammarota, Luisa Guidi
Marco Pizzoferrato, Pierluigi Puca, Sara Ennas, Giovanni Cammarota, Luisa Guidi, UOC Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome 00168, Italy
Pierluigi Puca, Giovanni Cammarota, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome 00168, Italy
Author contributions: All authors contributed to the conception and design of the study, drafting the article or making critical revisions related to important intellectual content of the manuscript; Pizzoferrato M, Cammarota G and Guidi L involved in the final approval of the version of the article to be published.
Conflict-of-interest statement: Guidi L consulted and/or lecture fees: AbbVie, Janssen, Pfizer, Shire, Takeda. All the other authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Luisa Guidi, MD, PhD, Professor, UOC Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 8, Rome 00168, Italy. luisa.guidi@policlinicogemelli.it
Received: September 10, 2022 Peer-review started: September 10, 2022 First decision: October 19, 2022 Revised: November 1, 2022 Accepted: November 17, 2022 Article in press: November 17, 2022 Published online: November 28, 2022 Processing time: 75 Days and 15.1 Hours
Abstract
Short bowel syndrome (SBS) with intestinal failure (IF) is a rare but severe complication of Crohn’s disease (CD), which is the most frequent benign condition that leads to SBS after repeated surgical resections, even in the era of biologics and small molecules. Glucagon-like peptide-2 analogues have been deeply studied recently for the treatment of SBS-IF. These drugs have a significant intestinotrophic effect and the potential to reduce the chronic dependence of SBS-IF patients on parenteral support or nutrition. Teduglutide has been approved for the treatment of SBS-IF, and apraglutide is currently in clinical development. The use of these drugs was examined with a focus on their use in CD patients.
Core Tip: Short bowel syndrome with intestinal failure and chronic dependency on parenteral support are rare but severe complications of Crohn’s disease (CD) after repeated intestinal resections. New therapeutic options are available, including glucagon-like peptide-2 analogues. Their use in CD appears safe and efficacious, but more data from specifically designed studies are needed.
